The World Health Organization has given its approval to the Covovax vaccination (Novavax Vaccine). Here are 10 important facts about this vaccine.
- The Serum Institute of India produces this Covovax vaccine under license from Novavax in the United States.
- The licensing of this vaccine is intended to satisfy the immunization requirements of low-income nations.
- Covovax is one of 9 vaccinations authorized by the World Health Organization thus far.
- Mariangela Simao, the Director-General of the World Health Organization, commented on this, saying, “The vaccine was licensed with the intention of bringing it to low-income nations. So far, 41 nations have vaccinated less than 10% of their populations, while the remaining 98 countries have vaccinated no more than 40%.”
- Covovax has been licensed for usage in the event of an emergency. The Serum Institute of India’s chief executive, Adar Poonawalla, described it as “another milestone in our fight against COVID-19.”
- Novavax, a pharmaceutical firm located in the United States, agreed to manufacture 200 crore doses of the vaccine with the Serum Institute of India in September.
- The Serum Institute of India’s Chief Executive Officer, Adar Poonawalla, had hoped that Novovax’s Covovax vaccine would be available in India by September.
- Adar Poonawalla has previously stated that the serum firm might apply for a license to manufacture based on the worldwide results of the vaccine’s clinical trial, even before the Novavax vaccine’s clinical trials were completed.
- There are two doses of the Novavax vaccination.
- In clinical studies in the United States, it was found to be 91% effective in preventing corona infections in individuals most at risk, and 100% effective in preventing moderate and severe corona infections.
Can a booster Novavax Vaccine prevents Omicron?
Covovax “induces a robust immune response and has an outstanding safety profile,” according to NSACOG’s Anurag Agrawal.
Covovax has been given emergency authorization by the World Health Organization (WHO), and a leading Indian government scientist has advised that it be administered as a booster injection to combat the threat presented by the developing omicron strain of coronavirus.
Covovax is an Indian version of the Covid-19 vaccine, which was created by Novavax Inc and is manufactured by the Serum Institute of India under license (SII). It’s a recombinant protein vaccine that employs spike proteins to train the body how to fight the new coronavirus.
According to Anurag Agrawal, Covovax is more effective as a booster dosage than Covishield. He did add, however, that further clinical research is needed to determine how much protection Novovax gives against the Omicron strain.
“I don’t believe the authorized version, which is based on ancestral spike protein, will be very efficient against Omicron because its efficiency against Beta was approximately 50%.” (much better than AZ though). As a booster, it’s better than the third dosage of AstraZeneca/Covishield,” he stated.
“The immune boost, following two doses of AZ/Covishield, was considerably better for this than inactivated viral vaccine in COV-BOOST,” Anurag Agrawal said, comparing Covovax’s immune response to data from COV-vaccination Boost’s study. In addition, fast protein modification for variant-specific immune responses is possible.”
In a clinical trial involving 29,960 participants in South Africa, the Novavax vaccine, also known as Covovax outside India, showed 90.4% efficiency. The effectiveness is comparable to Pfizer and Moderna’s competing candidates. According to the New York Times, it was 100% effective in avoiding moderate or severe illness.
The Phase III trials began in September 2020 in the United Kingdom, with a 96% effectiveness rate against the original coronavirus strain. The company is also working on vaccination to protect against additional Covid-19 versions.
Here, I create videos on Medicine, College students, Lifestyle, and Entrepreneurship, all of which are based on my personal experiences and studies.
Connect us & Be safe
News Analyst and Content manager.